Bottom line: clinical trial successes for IPIX's drugs have been stunning so far. This company is so ridiculously underpriced that even if only one drug were as successful as they all have been so far, the stock price should be at least double.

And we have 3 completely different drugs, for multiple applications, with successful clinical trials. In my opinion the stock price should be at a minimum of 5 right now, and that is really not pricing in the magnitude of the pipeline and the clinical trial successes.